ClinicaliQ Trial Snapshot
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia — Recruiting • Phase III • NCT07144163.
- A trial testing a new drug called atumelnant in adults with a genetic condition affecting the adrenal glands to check if it works, is safe, and how the body processes it.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD. Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia Interventions: Atumelnant, Placebo Lead Sponsor: Crinetics Pharmaceuticals Inc. Planned Enrollment: 150 participants